The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 11, 2016
Filed:
Nov. 13, 2013
Applicant:
Nant Holdings Ip, Llc, Los Angeles, CA (US);
Inventors:
Kayvan Niazi, Los Angeles, CA (US);
Shahrooz Rabizadeh, Los Angeles, CA (US);
Justin Golovato, Los Angeles, CA (US);
Patrick Soon-Shiong, Los Angeles, CA (US);
Anne-Laure Le Ny, South Pasadena, CA (US);
Oleksandr Buzko, Los Angeles, CA (US);
Assignee:
Nant Holdings IP, LLC, Culver City, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/76 (2006.01); A61K 31/42 (2006.01); A01N 43/08 (2006.01); A61K 31/34 (2006.01); A01N 43/20 (2006.01); A01N 43/24 (2006.01); A61K 31/335 (2006.01); A61K 31/423 (2006.01); A61K 31/05 (2006.01); A61K 31/12 (2006.01); A61K 31/365 (2006.01); A61K 31/404 (2006.01); A61K 31/407 (2006.01); A61K 33/24 (2006.01); A61K 9/00 (2006.01); A61K 47/06 (2006.01); A61K 47/10 (2006.01); A61K 31/341 (2006.01); A61K 31/16 (2006.01); A61K 31/66 (2006.01);
U.S. Cl.
CPC ...
A61K 31/423 (2013.01); A61K 9/0014 (2013.01); A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/16 (2013.01); A61K 31/341 (2013.01); A61K 31/365 (2013.01); A61K 31/404 (2013.01); A61K 31/407 (2013.01); A61K 31/66 (2013.01); A61K 33/24 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01);
Abstract
Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Caionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.